Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

International conference on breaking cycles of the past in societies affected by historical trauma presented from 5-8 December 2012
2012-11-28

Marguerite Barankitse from Burundi
28 November 2012

An interdisciplinary group of scholars, experts and practitioners from 24 countries around the world will gather at the University of the Free State (UFS) in Bloemfontein from 5 - 8 December 2012 for a conference on “Engaging the Other: Breaking Intergenerational Cycles of Repetition.”

The conference intends to open new avenues of inquiry into the trans-generational effects of trauma on communities that have experienced extreme violence.

One of the highlights of the conference is a presentation by Marguerite Barankitse, a survivor of the Rwandan genocide, on Thursday 6 December 2012. Marguerite has received several awards and distinctions for her work aimed at transforming the lives of Hutu and Tutsi children affected by war. Among these are the highly prestigious humanitarian prize, the Opus Prize, the UNESCO Prize, and the World's Children's Prize, also known as the ‘Nobel Prize’ for humanitarian work aimed at improving the lives of children and their chances of a better future.

On Saturday 8 December 2012 Prof. Martha Nussbaum, one of the world’s foremost philosophers, will deliver a keynote address on “Reconciliation: The political role of the Arts.” Prof. Nussbaum will receive a D.Litt. degree in the Faculty of Humanities from the UFS on 6 December 2012.

Other guests include Michael Lapsley, survivor of an apartheid bombing, Kimberlyn Leary, Associate Professor at Harvard Medical School,  Dr Jean Decety, Irving B. Harris Professor at the University of Chicago and Dr Katerina Fotopoulou from the Institute of Cognitive Neuroscience at the University College in London.

One of the conference events entitled “South Africans speak about the crisis of moral leadership: A public dialogue” will be open to the public and presented in the Centenary Complex on Friday 7 December 2012 from 18:00-19:30. Participants in the public dialogue include some of South Africa’s most thoughtful social commentators and a community activist: Barney Pityana (Professor and Rector, College of Transfiguration); Prince Mashele (Director: Centre for Politics and Research); Pierre de Vos (Professor of Law, University of Cape Town); and Faeza Meyer (Chairperson: Tafelsig Residents Unite).

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept